Pro-Apoptotic Effects of Plasma from Patients with Cardiorenal Syndrome on Human Tubular Cells.

This study seeks to provide insight into the pathophysiological pathways in CRS1; we evaluated in vitro the effects of CRS1 plasma on TECs. METHODS: We enrolled 40 acute HF patients and 15 controls (CTR) without HF or acute kidney injury (AKI). Ten out of 40 HF patients exhibited AKI at the time of admission for HF or developed AKI during hospitalization and were classified as CRS1. In vitro, cell viability, DNA fragmentation and caspase-3 levels were investigated in TECs incubated with HF, CRS1, and CTR plasma. We assessed inflammatory cytokines and NGAL expression at the gene and protein levels. RESULTS: We observed a marked pro-apoptotic activity and a significantly increased in vitro level of apoptosis in TECs incubated with plasma from CRS1 patients compared to HF and CTR (p
Source: American Journal of Nephrology - Category: Urology & Nephrology Authors: Tags: Am J Nephrol Source Type: research

Related Links:

No abstract available
Source: Journal of Hypertension - Category: Cardiology Tags: Correspondence Source Type: research
This ESH update was deemed necessary with the publication of new results of sham-controlled randomized blinded prospective trials with renal denervation (RDN). Proof of concept studies and first randomized trials (some were sham-controlled) displayed discrepant results about the efficacy of RDN. Three sham-controlled randomized trials of the 2.0 generation yielded now similarity in the average blood pressure decrease following RDN. Reduction of ambulatory blood pressure was approximately 5 to 7 mmHg and of office blood pressure 10 mmHg. Such a decrease in blood pressure by pharmacologic therapy has been found to be associa...
Source: Journal of Hypertension - Category: Cardiology Tags: Esh Statement Source Type: research
Conclusion: Our results suggest that heartbeat scaling and multifractal properties in CHF patients are not generated at the sinus-node level, but rather by the i- trinsic action of vagal short-term control and of sympatho-vagal fluctuations associated with circadian cardiovascular control especially within the very low frequency band. These markers might provide critical information in devising a clinical tool for individualized prediction of survivor and nonsurvivor CHF patients.
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
Studies have shown a positive association between systemic markers of inflammation and the risk of future cardiovascular disease. It is believed that this risk is mediated by prothrombotic changes in the vasculature as a response to inflammation. Systemic inflammatory diseases such as inflammatory bowel disease (IBD) may increase the risk for coronary artery disease by this mechanism, although prior epidemiologic studies show mixed results. In this issue of Clinical Gastroenterology and Hepatology, Aniwan and colleagues1 evaluated the risk of acute myocardial infarction and heart failure in patients with ulcerative colitis...
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Issue highlights Source Type: research
ConclusionsBE are common after MitraClip and are associated with an impaired outcome. Strategies to reduce bleeding events are paramount in this cohort of patients.
Source: IJC Heart and Vasculature - Category: Cardiology Source Type: research
AbstractPurpose of reviewHeart failure (HF) is prevalent among women and remains a leading cause of morbidity and mortality in the United States. Currently, 3  million women live with HF and the prevalence is projected to continue to increase. The purpose of this review is to highlight sex differences in the use and response to evidence-based pharmacological, device, and advanced HF therapies, as well as explore emerging areas of research in sex differen ces in the treatment of HF.Recent findingsUnder-representation of women in clinical HF trials has limited our understanding of sex-related differences in the treatmen...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
AbstractPurpose of reviewCardiovascular disease remains the leading cause of death in women. The goal of this review is to address known disparities in cardiovascular care with regard to diagnosis and treatment of heart disease in women.Recent findingsGender-specific differences in regard to the incidence, treatment, and outcomes of common cardiovascular pathology are increasingly recognized. Particular attention to ischemic heart disease, arrhythmia, congestive heart failure, and structural heart disease are reviewed in this article. There is a clear racial and ethnic discrepancy among women which is particularly concerni...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
S. Jay Olshansky is one of the researchers behind the Longevity Dividend initiative, a long-standing and fairly conservative academic initiative aimed at producing far greater funding for research to slow aging. It is one of a number of groups attempting to change the present academic and public research edifice from the inside. Olshansky recently issued a call to action, arguing for the research community to focus on increased healthspan rather than increased lifespan. From my perspective he makes this argument for all the wrong reasons, based on an expectation that it will prove impossible to produce large gains, say two...
Source: Fight Aging! - Category: Research Authors: Tags: Activism, Advocacy and Education Source Type: blogs
Trastuzumab, certain chemo treatments increase patient risk of heart failure
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, Pharmacy, Journal, Source Type: news
Conclusion: Chronic HF leads to latent kidney injury, associated with deep changes in kidney protein composition. These alterations may act in concert with intrarenal renin-angiotensin system activation and may serve as markers and/or targets to tackle cardiorenal syndrome.Kidney Blood Press Res 2018;43:1437 –1450
Source: Kidney and Blood Pressure Research - Category: Urology & Nephrology Source Type: research
More News: Cardiology | Genetics | Heart | Heart Failure | Study | Urology & Nephrology